Results 71 to 80 of about 4,367 (184)

Efficacy and Safety of Risankizumab in Patients with Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Rheumatology and Therapy
Introduction Currently, the cause of psoriatic arthritis (PsA) is unknown, and the effectiveness of current drug treatments is unsatisfactory. In March 2019, the US Food and Drug Administration (FDA) approved risankizumab, a humanized immunoglobulin G1 ...
Qin-Yi Su, Hao-Nan Zhou, Guo-Mei Xia, Rui-Yuan Zhang, Hong-Yuan Tian, Chang Su, Yu-Xin Liu, He-Yi Zhang, Ting Cheng, Yue-Hong Huo, Qian Li, Sheng-Xiao Zhang   +11 more
doaj   +1 more source

Comparative Effectiveness Analysis of Phase 3 Clinical Trials in Moderately to Severely Active Inflammatory Bowel Disease Reveals Increased Harm From Placebo and Challenges Equipoise

JCC Plus, Volume 1, Issue 5, September 2026.
Across 47 Phase 3 trials in Crohn's disease and ulcerative colitis, placebo exposure was associated with measurable harm. Disease exacerbation events showed the greatest excess risk, with one additional exacerbation occurring for every 8–13 patients assigned to placebo rather than active therapy.
Joëlle St‐Pierre, Zachary D. Fine, Evan N. Fear, Jeremy A. Klein, Natalie K. Choi, David T. Rubin   +5 more
wiley   +1 more source

Enthesitis and Dactylitis Resolution with Risankizumab for Active Psoriatic Arthritis: Integrated Analysis of the Randomized KEEPsAKE 1 and 2 Trials

Dermatology and Therapy
Introduction The presence (vs absence) of enthesitis/dactylitis is associated with greater psoriatic arthritis (PsA) activity and reduced health-related quality of life. Risankizumab, an interleukin 23 antagonist, demonstrated superior treatment efficacy
Shawn G. Kwatra, Saakshi Khattri, Ahmad Z. Amin, Roberto Ranza, Blair Kaplan, Linyu Shi, Byron Padilla, Ahmed M. Soliman, Dennis McGonagle   +8 more
doaj   +1 more source

Should TNF inhibitors be avoided in psoriasis patients with latent tuberculosis?

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Fabià Torres‐Betato, Lluís Puig
wiley   +1 more source

Indicators of Suboptimal Treatment Among Patients With Crohn's Disease Treated With Ustekinumab or Risankizumab and Treatment Journey Among Ustekinumab Discontinuers in the United States

JCC Plus, Volume 1, Issue 5, September 2026.
ABSTRACT Background and Aims Patients with Crohn's disease (CD) may experience suboptimal response to advanced therapies (ATs), including interleukin (IL)‐12/23 inhibitor ustekinumab and IL‐23 inhibitor risankizumab. In an evolving treatment landscape, this study evaluated indicators of suboptimal treatment with these agents. Methods This retrospective
Freddy Caldera, Maryia Zhdanava, Sumesh Kachroo, Lilian Diaz, Aditi Shah, Fengyi Jiang, Caroline Kerner, Dominic Pilon, Jennifer Seminerio   +8 more
wiley   +1 more source

Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease [PDF]

BACKGROUND The efficacy and safety of risankizumab as compared with ustekinumab in patients with Crohn's disease are unknown. METHODS In this phase 3b, multicenter, open-label, randomized, controlled trial with blinded assessment of end points, patients ...
Anschutz, Toni, Panaccione, Remo, Panaccione, R, Ferrante, Marc, D'Haens, Geert, Anschutz, T, Caprioli, F, Atreya, Raja, Schreiber, S, Schreiber, Stefan, Neimark, Ezequiel, Lindsay, JO, Shu, L, SEQUENCE Study Group, Berg, S, Rahier, Jean-François, Danese, Silvio, Siegmund, Britta, Ferrante, M, Dubinsky, Marla, Gionchetti, Paolo, Peyrin-Biroulet, Laurent, Pivorunas, V, Chapman, JC, Cao, Qian, Bossuyt, Peter, Caprioli, Flavio, Chapman, J Casey, Huang, Xiu, Atreya, R, Berg, Sofie, Peyrin-Biroulet, L, Siegmund, B, Cao, Q, Kligys, Kristina, Duan, W Rachel, Duan, WR, Pivorunas, Valerie, Kligys, K, Huang, X, Wallace, Kori, SEQUENCE Study, Dubinsky, M, Bossuyt, P, Shu, Lei, Danese, S, Neimark, E, Colombel, J-F, Wallace, K, Lindsay, James O, D'Haens, G, Colombel, Jean-Frederic, Irving, PM, Irving, Peter M   +53 more
core   +1 more source

Isolated Mild Hyperemia Identified by Intestinal Ultrasound Is Associated With Adverse Outcomes in Inflammatory Bowel Disease

JCC Plus, Volume 1, Issue 5, September 2026.
ABSTRACT Background Increased bowel wall thickness (BWT) measured by intestinal ultrasound (IUS) is the most predictive sonographic parameter of endoscopic disease activity in Crohn's disease (CD) and ulcerative colitis (UC). The clinical significance of hyperemia in the absence of increased BWT has yet to be delineated.
Noa Krugliak Cleveland, Khushi S. Bhondwe, Charlotte M. Duty, Evan N. Fear, Tessa George, Qamar Nisa Ayoub, Benjamin D. McDonald, Amelia Kellar, David T. Rubin   +8 more
wiley   +1 more source

Risankizumab treatment in psoriasis patients who failed anti-IL17: a 52-week real-life study

, 2022
Background: Recent knowledge on the key role of interleukin (IL)23/17 axis in psoriasis pathogenesis, led to development of new biologic drugs. Risankizumab is a humanized immunoglobulin G1 monoclonal antibody specifically targeting IL23.
Camela, Elisa, Potestio, Luca, Megna, Matteo, Fabbrocini, Gabriella, Ruggiero, Angelo   +4 more
core   +1 more source

Single-cell RNA sequencing and in vitro validation reveal risankizumab induces anti-inflammatory macrophage polarization in psoriasis

European Journal of Medical Research
Background Risankizumab was an approved novel drug by Japan for psoriasis, we aimed to explore its underlying therapeutic mechanism through the single-cell RNA sequencing (scRNA-seq) technology.
Yuan Yuan, Linzi Li, Lihong Yang, Jiyuan Zheng, Guang Gao, Ting Tan, Jing Liu, Wen Sun   +7 more
doaj   +1 more source

Efficacy of Advanced Medical Therapies in Patients With Moderately to Severely Active Ulcerative Colitis: A Systematic Review and Meta‐Analysis

JCC Plus, Volume 1, Issue 5, September 2026.
This systematic review and meta‐analysis quantify absolute outcome differences of advanced therapies in moderate‐to‐severe ulcerative colitis, demonstrating significant benefits in clinical, endoscopic, and histological remission, and establishing a benchmark for evaluating novel or non‐pharmacological treatment strategies.
E. Visser, I. D. van Dijk, G. L. Burchell, W. A. Bemelman, G. R. D'Haens, C. J. Buskens   +5 more
wiley   +1 more source